Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the phenylpyridine class of organic compounds. It is structurally characterized by a pyridine core substituted with phenyl, trifluoromethyl, and methylaminosulfonyl groups. The compound has been cataloged in several chemical and drug databases (DrugBank DB08614, ChEMBL1236262) and is primarily referenced as an experimental or research ligand rather than a marketed pharmaceutical product. Its most notable biochemical activity is as a potent inhibitor of chymotrypsin-like elastase family member 1 (CELA1), with reported nanomolar affinity (Ki = 18 nM) in protein-ligand binding studies using porcine enzyme models[4]. There are no approved therapeutic indications or clinical development programs associated with this molecule.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-[[(methylamino)sulfonyl]amino]-2-oxo-6-phenyl-n-[3,3,3-trifluoro-1-(1-methylethyl)-2-oxophenyl]-1(2h)-pyridine acetamide.